Cover Image
市場調查報告書

Molecular Partners AG:產品平台分析

Molecular Partners AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253736
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Molecular Partners AG:產品平台分析 Molecular Partners AG - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 30 Pages
簡介

Molecular Partners AG是致力於生技藥品之研究開發及商品化之生物製藥公司,總公司位於瑞士的蘇黎世。該公司的產品活用於腫瘤,發炎,眼科等領域。

本報告提供Molecular Partners AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Molecular Partners AG的基本資料

  • Molecular Partners AG概要
  • 主要資訊
  • 企業資料

Molecular Partners AG:R&D概要

  • 主要的治療範圍

Molecular Partners AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Molecular Partners AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Molecular Partners AG :藥物簡介

  • MP-0250
  • MP-0274
  • Recombinant Protein 1 for Cancer
  • Recombinant Protein 2 for cancer
  • Recombinant Proteins 1 for Ophthalmology
  • Recombinant Proteins 2 for Ophthalmology
  • Recombinant Proteins 3 for Ophthalmology
  • Recombinant Proteins 4 for Opthalmology
  • Recombinant Proteins 5 for Ophthalmology

Molecular Partners AG :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Molecular Partners AG :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07196CDB

Summary

Global Markets Direct's, 'Molecular Partners AG - Product Pipeline Review - 2015', provides an overview of the Molecular Partners AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Molecular Partners AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Molecular Partners AG's pipeline products

Reasons to buy

  • Evaluate Molecular Partners AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Molecular Partners AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Molecular Partners AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Molecular Partners AG Snapshot
    • Molecular Partners AG Overview
    • Key Information
    • Key Facts
  • Molecular Partners AG - Research and Development Overview
    • Key Therapeutic Areas
    • Molecular Partners AG - Pipeline Review
  • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Molecular Partners AG - Pipeline Products Glance
    • Molecular Partners AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Molecular Partners AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Molecular Partners AG - Drug Profiles
    • MP-0250
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MP-0274
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein 1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein 2 for cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins 1 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins 2 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins 3 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins 4 for Opthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins 5 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Molecular Partners AG - Pipeline Analysis
  • Molecular Partners AG - Pipeline Products by Target
  • Molecular Partners AG - Pipeline Products by Route of Administration
  • Molecular Partners AG - Pipeline Products by Molecule Type
  • Molecular Partners AG - Pipeline Products by Mechanism of Action
  • Molecular Partners AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Molecular Partners AG, Key Information
  • Molecular Partners AG, Key Facts
  • Molecular Partners AG - Pipeline by Indication, 2015
  • Molecular Partners AG - Pipeline by Stage of Development, 2015
  • Molecular Partners AG - Monotherapy Products in Pipeline, 2015
  • Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
  • Molecular Partners AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Molecular Partners AG - Phase I, 2015
  • Molecular Partners AG - Preclinical, 2015
  • Molecular Partners AG - Discovery, 2015
  • Molecular Partners AG - Pipeline by Target, 2015
  • Molecular Partners AG - Pipeline by Route of Administration, 2015
  • Molecular Partners AG - Pipeline by Molecule Type, 2015
  • Molecular Partners AG - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Molecular Partners AG - Pipeline by Top 10 Indication, 2015
  • Molecular Partners AG - Pipeline by Stage of Development, 2015
  • Molecular Partners AG - Monotherapy Products in Pipeline, 2015
  • Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
  • Molecular Partners AG - Pipeline by Top 10 Target, 2015
  • Molecular Partners AG - Pipeline by Top 10 Molecule Type, 2015
  • Molecular Partners AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top